Business Context and Reporting Period
This Form 8-K is a current report filed by Uppercut Brands, Inc. (not Silo Pharma, Inc., as indicated in the metadata) on January 16, 2020. The filing addresses corporate governance changes under Item 5.02, specifically the departure of three directors and the appointment of a new director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes and does not contain financial statements or operational metrics.
Material Changes
- Director Resignations: On January 16, 2020, Joel A. Stone, Leonard Schiller, and Van E. Parker resigned from their positions as Directors. The Board formally accepted these resignations on the same date.
- Director Appointment: On January 16, 2020, the Board appointed Wayne D. Linsley to fill one of the vacancies.
- Future Appointments: The Company intends to fill the remaining board vacancies with members possessing experience complementary to current operations.
Outlook, Risks, and Management Commentary
Management Commentary: The Company stated there are no disputes or disagreements between the resigning directors and the Company. The resigning directors provided no written correspondence in response to the filing.
New Director Background: Wayne D. Linsley, 63, is an entrepreneur with over 40 years of experience in real estate, finance, and telecommunications. Since 2011, he has served as Vice President of Operations for CFO Oncall, Inc.
Risks and Litigation: The filing confirms that none of the appointees have been subjects of bankruptcy petitions, criminal convictions, or regulatory orders limiting their activities in the past ten years.
Material Plans: There are currently no material plans, contracts, or other arrangements with the new appointees.
Key Facts for Investor Verification
- Verify the total number of remaining board vacancies after the appointment of Mr. Linsley.
- Confirm the timeline for filling the remaining board seats.
- Review subsequent filings to determine if the resignations of Mr. Stone, Mr. Schiller, and Mr. Parker were related to any undisclosed operational or financial issues.
- Note the discrepancy between the metadata company name (Silo Pharma, Inc.) and the actual registrant (Uppercut Brands, Inc.).